drugset / Trial / NCT06708637

Ocular Safety and Usability Study for FYB203 PFS

NCT06708637

Phase 4 Completed 30 enrolled Formycon AG
NaSingle-groupOpen-labelTreatment

Summary

The objective of the study is to assess the ocular safety of the FYB203 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.

Timeline

Start
2024-09-20
Primary completion
2024-10-08
Completion
2024-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal